###### Key message

-   What is the association between self-reported physical activity (PA) and the rate of outpatient treated acute exacerbations of chronic obstructive pulmonary disease (AECOPD) ?

-   The association between self-reported moderate to vigorous PA and the rate of mild to moderate outpatient treated AECOPD over 2 years of follow-up was generally weak or not significant.

-   This is the largest cohort study using real-world data on patient self-reported PA and mild to moderate COPD exacerbations obtained from electronic medical records.

Background {#s1}
==========

Observational studies consistently show that physical inactivity is associated with increased hospitalisations and mortality.[@R1] We previously showed that hospitalised patients with chronic obstructive pulmonary disease (COPD) who were physically active in the year prior to the index admission had a 34% lower risk of 30-day readmission[@R6] and up to 47% lower risk of mortality in the 12 months following hospital discharge[@R7] compared with inactive patients. Very little has been published regarding the relationship between physical activity (PA) and outpatient treated, mild to moderate acute exacerbations of chronic obstructive pulmonary disease (AECOPD) that do not result in hospitalisations. The purpose of this study was to determine the association between self-reported moderate to vigorous PA, captured as part of routine care in a large integrated healthcare system, and the rate of outpatient treated AECOPD over 2 years.

Methods {#s2}
=======

Study design and setting {#s2-1}
------------------------

We performed a retrospective cohort study using longitudinal electronic medical record (EMR) data from Kaiser Permanente Southern California (KPSC) and Kaiser Permanente Pacific Northwest (KPNW) healthcare systems. We identified all patients aged \>40 years old with diagnosed COPD between January 2011 and September 2015 based on having ≥1 encounter with an International Classification of Diseases, Ninth Revision, code for COPD (491. XX, 492. XX, 493.2X and 496) and ≥1 dispensed inhaler. Baseline sociodemographic and clinical characteristics, Charlson Comorbidity Index,[@R8] spirometry, lifestyle behaviours, inhaler use and healthcare use were obtained in the year prior to exacerbation ascertainment (October 2014--September 2015).

Self-reported PA {#s3}
================

Every patient, regardless of their condition or presenting problem in the health system, is asked two questions that capture their regular PA during the intake process for all outpatient visits.[@R9] This is called the exercise vital sign (EVS) and is presented as (1) 'On average, how many days per week do you engage in moderate to strenuous (vigorous) exercise (like a brisk walk)?' and (2) 'On average, how many minutes do you engage in exercise at this level?' These questions are typically asked by front office medical staff, and patients\' responses are entered into the EMR. Response choices for days are categorical (0--7). Minutes are recorded as 0, 10, 20, 30, 40, 50, 60, 90, 120 and 150 min or greater. The EMR then multiplies the responses to display total minutes per week of moderate or vigorous PA. Patients can be categorised into three cohorts as used by the National Health and Examination Survey: inactive (0 min/week), insufficiently active (1--149 min/week) or active, meeting PA recommendations (≥150 min/week). We used all available EVS data in the year prior to ascertainment of COPD exacerbations to classify patients into their usual pattern of PA based on both the modal/median EVS values. The EVS has evidence of construct and predictive validity.[@R6]

COPD exacerbations {#s4}
==================

Two years of follow-up data for outpatient treated AECOPD were obtained from October 2015 to September 2017 via pharmacy and use data. AECOPD have been identified by changes in the current therapy to include increased use of bronchodilators and a short course of prednisone and/or antibiotics.[@R11] For this study, an outpatient AECOPD was defined as (1) encounters with a documented COPD diagnosis followed by a prescription fill of antibiotics, steroids, or antibiotics and steroids and (2) encounters with no documented COPD diagnosis but followed by a prescription fill of antibiotics and steroids, both within 2 days of the encounter; this definition yielded a sensitivity of 67% and a specificity of 84% based on a review of 185 charts.[@R12]

Statistical analyses {#s5}
====================

We used Poisson regression models to compare crude and adjusted rates of outpatient AECOPD per member-year; the log of the latter was included as an offset term. Covariates in adjusted models included age, gender, marital status, race/ethnicity, smoking status, use of inhaled steroids and oxygen, Charlson index, depression, anxiety, chronic pain, all-cause acute care use (hospitalisation, observation stay and ED visits) and number of outpatient treated AECOPD in the previous 12 months. Models were stratified by availability of spirometry and by Global initiative for chronic obstructive lung disease (GOLD) class. We also used negative binomial models to assess the sensitivity of our findings to possible overdispersion in AECOPD counts. Analyses were conducted using SAS V.9.4. A two-sided p value of \<0.05 was considered statistically significant.

Patient and public involvement {#s6}
==============================

Since this study strictly relied on existing data via an approved waiver of written consent, we did not engage with patient stakeholders in the design or conduct of the analyses nor interpretation of the findings.

Results {#s7}
=======

Baseline characteristics {#s7-1}
------------------------

Among 44 896 eligible adults with COPD, 56% were physically inactive; 23% were insufficiently active; and 21% were active. There were clinically and statistically meaningful differences in the gender distribution, smoking status, body mass index, GOLD class, oxygen use, comorbidities, and baseline all-cause and COPD-specific healthcare use across the PA categories ([tables 1 and 2](#T1 T2){ref-type="table"}). Approximately a quarter of the patients did not have spirometry data (25%) or had an forced expiratory volume in one second (FEV~1~):forced vital capacity (FVC) ratio of ≥0.70 (26%). Patients who were inactive experienced more outpatient treated AECOPD at baseline compared with other patients.

###### 

Baseline sociodemographic and clinical characteristics by self-reported moderate to vigorous physical activity (exercise vital sign)

                                                   Inactive (n=25 117)   Insufficiently active (n=10 221)   Active (n=9558)   P value
  ------------------------------------------------ --------------------- ---------------------------------- ----------------- ---------
  Age (years)                                      71.6 (10.53)          70.5 (10.37)                       69.5 (9.97)       \<0.01
   40--49                                          573 (2%)              293 (3%)                           311 (3%)          \<0.01
   50--59                                          2894 (12%)            1231 (12%)                         1217 (13%)        
   60--69                                          6647 (26%)            3038 (30%)                         3026 (32%)        
   70--79                                          8923 (36%)            3590 (35%)                         3491 (37%)        
   80+                                             6080 (24%)            2069 (20%)                         1513 (16%)        
  Female                                           14 129 (56%)          5545 (54%)                         4307 (45%)        \<0.01
  Marital status: partnered                        12 988 (52%)          5502 (54%)                         5486 (57%)        \<0.01
  Education: college+                              6238 (25%)            2795 (28%)                         2910 (31%)        \<0.01
  Median household income: ≥\$50 000               14 156 (57%)          5884 (58%)                         5684 (60%)        \<0.01
  Race/ethnicity: white                            19 637 (78%)          7374 (72%)                         7273 (76%)        \<0.01
  Insurance status: public                         18 142 (72%)          6959 (68%)                         6543 (68%)        \<0.01
  Smoking status                                                                                                              \<0.01
   Never                                           4248 (17%)            2126 (21%)                         2027 (21%)        
   Former                                          15 615 (62%)          6326 (62%)                         6016 (63%)        
   Current                                         5037 (20%)            1687 (17%)                         1431 (15%)        
   Missing                                         217 (1%)              82 (1%)                            84 (1%)           
  Body mass index                                  30.2 (27.81)          28.9 (6.97)                        27.7 (6.77)       \<0.01
   Underweight (\<18.5)                            775 (3%)              240 (2%)                           246 (3%)          \<0.01
   Normal weight (18.5--24.9)                      5868 (23%)            2774 (27%)                         3149 (33%)        
   Overweight (25.0--29.9)                         7407 (29%)            3446 (34%)                         3315 (35%)        
   Obese (\>30)                                    10 860 (43%)          3693 (36%)                         2779 (29%)        
   Missing                                         207 (1%)              68 (1%)                            69 (1%)           
  Spirometry                                       18 479 (74%)          7768 (76%)                         7261 (76%)        
   FEV~1~/FVC\<0.70                                11 802 (47%)          5035 (49%)                         4910 (51%)        \<0.01
   FEV~1~/FVC                                      63.8 (13.39)          63.5 (13.29)                       63.2 (12.63)      \<0.01
   FEV~1~% predicted                               72.6 (21.68)          74.4 (22.16)                       77.3 (33.83)      \<0.01
   GOLD I (≥80%)                                   2795 (11%)            1322 (13%)                         1616 (17%)        \<0.01
   GOLD II (50%≤FEV~1~\<80%)                       6401 (26%)            2695 (26%)                         2517 (26%)        
   GOLD III/IV (FEV~1~\<50%)                       2605 (10%)            1018 (10%)                         777 (8%)          
   FEV~1~/FVC≥0.7                                  6677 (27%)            2733 (27%)                         2351 (25%)        
  No spirometry                                    6639 (26%)            2453 (24%)                         2297 (24%)        
  Medications (use in 2015)                                                                                                   
   LABAs                                           8628 (34%)            3452 (34%)                         3112 (33%)        \<0.01
   LAMA                                            7332 (29%)            2797 (27%)                         2361 (25%)        \<0.01
   ICS                                             8804 (35%)            3512 (34%)                         3195 (33%)        0.02
   LAMA and ICS                                    3850 (15%)            1448 (14%)                         1131 (12%)        \<0.01
   LABA and ICS                                    8367 (33%)            3335 (33%)                         3018 (32%)        \<0.01
   Long-term systemic corticosteroids              311 (1%)              107 (1%)                           82 (1%)           \<0.01
   Oxygen use                                      4310 (17%)            1154 (11%)                         656 (7%)          \<0.01
  Comorbidities (all available data, 2011--2015)                                                                              
  Charlson Comorbidity Index                       3.5 (2.41)            3.0 (2.15)                         2.6 (1.99)        \<0.01
   Quartile 1 (0--1)                               5538 (22%)            2847 (28%)                         3289 (34%)        \<0.01
   Quartile 2 (2)                                  5144 (20%)            2491 (24%)                         2344 (25%)        
   Quartile 3 (3-4)                                7334 (29%)            2811 (28%)                         2451 (26%)        
   Quartile 4 (\>4)                                7099 (28%)            2072 (20%)                         1474 (15%)        
   Myocardial infarction                           3028 (12%)            947 (9%)                           836 (9%)          \<0.01
   Congestive heart failure                        4480 (18%)            1168 (11%)                         820 (9%)          \<0.01
   Peripheral vascular disease                     13 958 (56%)          5034 (49%)                         4233 (44%)        \<0.01
   Cerebrovascular disease                         2548 (10%)            755 (7%)                           557 (6%)          \<0.01
   Dementia                                        361 (1%)              72 (1%)                            27 (0%)           \<0.01
   Connective tissue disease--rheumatic disease    1319 (5%)             424 (4%)                           336 (4%)          \<0.01
   Peptic ulcer disease                            356 (1%)              95 (1%)                            76 (1%)           \<0.01
   Mild liver disease                              1551 (6%)             514 (5%)                           506 (5%)          \<0.01
   Diabetes without complications                  2967 (12%)            1289 (13%)                         1013 (11%)        \<0.01
   Diabetes with complications                     5424 (22%)            1636 (16%)                         1121 (12%)        \<0.01
   Paraplegia and hemiplegia                       308 (1%)              63 (1%)                            47 (0%)           \<0.01
   Renal disease                                   7463 (30%)            2459 (24%)                         1863 (19%)        \<0.01
   Cancer                                          1879 (7%)             612 (6%)                           596 (6%)          \<0.01
   Moderate or severe liver disease                142 (1%)              41 (0%)                            41 (0%)           0.06
   Metastatic carcinoma                            419 (2%)              140 (1%)                           93 (1%)           \<0.01
  Other non-Charlson morbidities                                                                                              
   Depression                                      7197 (29%)            2365 (23%)                         1763 (18%)        \<0.01
   Anxiety                                         5441 (22%)            1805 (18%)                         1489 (16%)        \<0.01
   Chronic pain                                    5502 (22%)            1531 (15%)                         1265 (13%)        \<0.01

FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; GOLD, Global initiative for chronic obstructive lung disease; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting anticholinergic.

###### 

Baseline healthcare use by self-reported moderate to vigorous physical activity (exercise vital sign)

                                                  Inactive (n=25 117)   Insufficiently active (n=10 221)   Active (n=9558)   P value
  ----------------------------------------------- --------------------- ---------------------------------- ----------------- ---------
  Baseline healthcare use (Oct 2014--Sept 2015)                                                                              
   All cause                                                                                                                 
   Hospitalisations                               5869 (23%)            1461 (14%)                         1036 (11%)        \<0.01
  0.4 (0.93)                                      0.2 (0.64)            0.2 (0.58)                         \<0.01            
   Observational stays                            1830 (7%)             485 (5%)                           338 (4%)          \<0.01
  0.1 (0.34)                                      0.1 (0.25)            0.0 (0.26)                         \<0.01            
   Emergency department visits                    9258 (37%)            2829 (28%)                         2369 (25%)        \<0.01
  0.8 (1.74)                                      0.5 (1.26)            0.4 (1.33)                         \<0.01            
   Primary care visits                            4.9 (4.75)            4.2 (3.92)                         4.1 (4.27)        \<0.01
   Specialty care visits                          9.7 (12.48)           8.2 (10.82)                        8.4 (12.51)       \<0.01
  COPD-related acute care encounters                                                                                         
   Hospitalisations                               1045 (4%)             258 (3%)                           141 (1%)          \<0.01
  0.2 (0.47)                                      0.1 (0.33)            0.1 (0.26)                         \<0.01            
   Observational stays                            244 (1%)              73 (1%)                            35 (0%)           \<0.01
  0.0 (0.18)                                      0.0 (0.16)            0.0 (0.12)                         \<0.01            
   Emergency department visits                    1208 (5%)             359 (4%)                           226 (2%)          \<0.01
  0.2 (0.56)                                      0.1 (0.44)            0.1 (0.37)                         \<0.01            
   Outpatient treated exacerbations               9550 (38%)            3340 (33%)                         2992 (31%)        \<0.01
  0.7 (1.16)                                      0.5 (1.00)            0.5 (1.00)                         \<0.01            

COPD, chronic obstructive pulmonary disease.

Association between PA and rate of outpatient treated COPD exacerbations over 2 years {#s7-2}
-------------------------------------------------------------------------------------

For the overall cohort, the unadjusted model showed a lower rate of AECOPD in the insufficiently active and active groups compared with the inactive group, but this was no longer significant in the adjusted model for the insufficiently inactive group (incidence rate ratio (adjusted IRR) 0.98, 95% CI 0.96 to 1.01) and only marginally meaningful for the active group (adjusted IRR 0.97, 95% CI 0.95 to 0.98) ([table 3](#T3){ref-type="table"}). There were no significant associations between PA and AECOPD for patients in GOLD classes I and II. For GOLD III/IV patients, there appears to be some marginal though non-significant association between any PA and AECOPD (adjusted IRR 0.95, 95% CI 0.90 to 1.00) compared with inactive patients. For patients with FEV~1~:FVC of ≥0.70, the adjusted model showed that insufficiently active patients had lower AECOPD risk compared with inactive patients (IRR 0.90, 95% CI 0.85 to 0.95). No significant associations were noted for patients who did not have spirometry data. The negative binomial models provided similar point estimates but with wider CIs.

###### 

Association between self-reported moderate to vigorous physical activity and rate of outpatient treated COPD exacerbations over 2 years of follow-up

  -----------------------------------------------------------------------------------------------------------------------------
                                    Outpatient treated\         Crude IRR   Unadjusted IRR (95% CI)   Adjusted IRR\* (95% CI)
                                    COPD exacerbations\                                               
                                    n (%), mean (SD)                                                  
  --------------------------------- --------------------------- ----------- ------------------------- -------------------------
  All patients (N=44 896)                                                                             

   Inactive (25 117)                12 483 (50%), 1.24 (2.04)   Ref         Ref                       Ref

   Insufficiently active (10 221)   4882 (48%), 1.14 (1.90)     0.92        0.93 (0.91 to 0.95)       0.98 (0.96 to 1.01)

   Active (9558)                    4440 (46%), 1.07 (1.84)     0.86        0.86 (0.84 to 0.88)       0.97 (0.95 to 0.98)

  FEV~1~/FVC\<0.7 (n=21 746)                                                                          

  GOLD I (n=5733)                                                                                     

   Inactive (2795)                  1330 (48%), 1.09 (1.87)     Ref         Ref                       Ref

   Insufficiently active (1322)     581 (44%), 0.95 (1.64)      0.87        0.89 (0.84 to 0.95)       1.03 (0.97 to 1.11)

   Active (1616)                    722 (45%), 0.95 (1.62)      0.87        0.88 (0.83 to 0.93)       1.0 (0.94 to 1.07)

  GOLD II (n=11 613)                                                                                  

   Inactive (6401)                  3570 (56%), 1.47 (2.20)     Ref         Ref                       Ref

   Insufficiently active (2695)     1461 (54%), 1.37 (2.16)     0.93        0.94 (0.91 to 0.98)       0.99 (0.95 to 1.04)

   Active (2517)                    1355 (54%), 1.29 (2.01)     0.88        0.88 (0.85 to 0.92)       1.02 (0.98 to 1.06)

  GOLD III/IV (n=4400)                                                                                

   Inactive (2605)                  1737 (67%), 2.22 (2.85)     Ref         Ref                       Ref

   Insufficiently active (1018)     648 (64%), 1.97 (2.66)      0.89        0.90 (0.85 to 0.94)       0.95 (0.9 to 1.0)

   Active (777)                     517 (67%), 2.04 (2.69)      0.92        0.93 (0.88 to 0.98)       0.95 (0.9 to 1.0)

  FEV~1~/FVC≥0.7 (n=11 761)                                                                           

   Inactive (6677)                  2843 (43%), 0.91 (1.61)     Ref         Ref                       Ref

   Insufficiently active (2733)     1097 (40%), 0.84 (1.5)      0.92        0.93 (0.89 to 0.98)       0.9 (0.85 to 0.95)

   Active (2351)                    876 (37%), 0.72 (1.39)      0.79        0.79 (0.75 to 0.83)       1.05 (0.98 to 1.12)

  No spirometry (n=11 389)                                                                            

   Inactive (6639)                  3003 (45%), 1.03 (1.78)     Ref         Ref                       Ref

   Insufficiently active (2453)     1095 (45%), 0.97 (1.57)     0.94        0.95 (0.90 to 0.99)       0.97 (0.92 to 1.03)

   Active (2297)                    970 (42%), 0.93 (1.69)      0.90        0.91 (0.86 to 0.95)       1.03 (0.98 to 1.08)
  -----------------------------------------------------------------------------------------------------------------------------

\*Adjusted models accounted for age, gender, marital status, race/ethnicity, smoking status, use of inhaled steroids and oxygen, comorbidity, depression, anxiety, chronic pain, all-cause acute care use (hospitalisation, observation stay and emergency department visits), and baseline outpatient treated COPD exacerbations in the previous 12 months. Sample sizes for unadjusted and adjusted models may vary by \~100 to 345 fewer than the listed n for each subgroup primarily due to missing body mass index (n=344).

COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; GOLD, Global initiative for chronic obstructive lung disease; IRR, incidence rate ratio; Ref, reference.

Discussion {#s8}
==========

We found that the association between baseline moderate to vigorous PA captured as part of routine care and the rate of mild to moderate outpatient treated AECOPD over 2 years of follow-up was generally weak or non-significant, which is in contrast to the strong relationship observed between PA and hospitalisations for severe exacerbations, despite differences in how PA was measured and classified across these prior studies.[@R1] To the best of our knowledge, this is the first 'real-world' large-scale study to examine the association between self-reported PA, captured during routine care, with AECOPD in an entire clinical population of patients diagnosed with COPD from an integrated healthcare system.

The weak to null findings in this study could partly be attributed to the difficulty of capturing AECOPD in the EMR and incomplete ascertainment of these events in contrast to near complete capture of severe AECOPD that result in hospitalisations, in combination with the imprecision and errors associated with self-reported PA.[@R13] Given the need for any behavioural assessment to be streamlined for use in routine care across broad populations and for different clinical and population surveillance purposes,[@R14] the self-reported measure of PA used in this study only provides an overall assessment of 'regular' PA in the previous year and did not distinguish between light, moderate and vigorous activities.[@R9] A recent study of 177 patients with stable COPD that measured PA with an accelerometer over an 8-day period found that for every increase of 1000 daily steps at low average intensity, the risk of COPD hospitalisation was reduced by 20% over a 2-year period; high-intensity PA was not associated with any risk reduction.[@R5] In our previous paper, using the same self-reported moderate to vigorous PA measure as the current study, we also found a significant risk reduction (34%) in 30-day readmissions for 4596 patients with COPD who reported engaging in any amount of PA.[@R6] It is possible that, although the PA questions asked about moderate to vigorous exercise, patients may have actually reported on what would be perceived as lower intensity activities in normal adults without airflow obstruction and that the challenge we faced in this study had more to do with difficulties capturing the AECOPD events using data that were intended for clinical care, not research purposes. Interestingly, a recent meta-analysis of 39 studies reported that higher levels of total PA, *at any intensity*, was associated with lower risk of mortality.[@R15]

Another limitation of the study was that our models did not include other intervening events and changes in PA patterns over the 2 years of follow-up. With broader use of biometric sensors, future studies could improve on these methods by using objective PA data combined with electronic logs of symptoms, sensors to detect changes in breathing patterns and treatments to explore the real-time, dynamic relationships between different PA intensities and AECOPD across a broad, representative population of patients with COPD.[@R16]

In conclusion, although our findings show little to no association between PA and the rate of AECOPD based on data obtained as part of routine clinical care, the positive health effects of PA is indisputable based on the existing high-quality evidence base regarding the survival benefits of PA in COPD[@R1] and healthy adults and older adults.[@R15]
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